---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-24-000122"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:26:41.784694+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cartesian Q3 net loss $(24.2)M; cash $220.9M; Phase 3 Descartes-08 in MG expected 1H2025

## Summary
- Cash and equivalents $220.9M as of Sep 30, 2024; runway expected into mid-2027.
- Net loss $(24.2)M ($(1.13)/share) vs $(9.0)M ($(1.74)) in Q3 2023.
- Research and development expenses $11.4M, down from $13.0M year-over-year.
- Plan to commence Phase 3 trial of Descartes-08 in myasthenia gravis in 1H2025 after FDA meeting.
- Completed $130M PIPE financing in July 2024; first patient dosed in Phase 2 SLE trial.

## SEC filing metadata
- accession: 0001453687-24-000122
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/0001453687-24-000122-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368724000122/rnac-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-24-000122
- JSON: https://secwatch.observer/filing/0001453687-24-000122.json
- Plain text: https://secwatch.observer/filing/0001453687-24-000122.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.